Miller-Fisher Syndrome

Watchlist
Retrieved
2022-04-26
Source
Trials
Genes

Miller Fisher syndrome is a rare acquired nerve disease considered to be a variant of syndrome">Guillain-Barré syndrome. The main features are lack of muscle coordination (ataxia), eye muscle weakness resulting in the inability to move the eyes in several directions (ophthalmoplegia), and the absence of tendon reflexes. Symptoms often start several days after a viral illness. Other symptoms include generalized muscle weakness and respiratory failure. The cause is not known, but it is thought to be an autoimmune disease in which there are autoantibodies that attack the nerves. In most people with Miller Fisher syndrome an antibody (anti-GQ1b) is identified. The presence of these autoantibodies helps confirm the diagnosis of the syndrome. Treatment includes intravenous immunoglobulin (IVIG), plasmapheresis (a plasma exchange procedure in which the antibodies are removed from the blood) and supportive care. The prognosis is usually good, and in most cases, there is almost complete recovery within 6 months. In rare cases, the syndrome may progress and permanent neurological deficits may be present.